

RealRate

PHARMACEUTICAL 2018

KalVista Pharmaceuticals Inc. Rank 81 of 342









RealRate

PHARMACEUTICAL 2018

KalVista Pharmaceuticals Inc. Rank 81 of 342



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 136% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	34,248
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,018
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-2,568
Other Expenses	0
Other Liabilities	0
Other Net Income	5,240
Other Revenues	0
Property and Equipment	97
Research and Development	12,666
Selling, General and Administrative Expense	11,177

Output Variable	Value in 1000 USD
Assets	34,345
Liabilities	3,018
Expenses	23,843
Revenues	0
Stockholders Equity	31,327
Net Income	-18,603
Comprehensive Net Income	-19,887
Economic Capital Ratio	182%

